Zacks Investment Research Downgrades Compugen (NASDAQ:CGEN) to Hold

Zacks Investment Research downgraded shares of Compugen (NASDAQ:CGEN) from a buy rating to a hold rating in a research note published on Monday morning, Zacks.com reports.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Separately, ValuEngine raised Compugen from a sell rating to a hold rating in a research report on Saturday.

Shares of NASDAQ CGEN traded down $0.02 during midday trading on Monday, hitting $3.99. The stock had a trading volume of 3,869 shares, compared to its average volume of 86,901. The company has a market capitalization of $208.49 million, a price-to-earnings ratio of -9.73 and a beta of 2.60. Compugen has a 1-year low of $2.00 and a 1-year high of $4.50. The company has a quick ratio of 5.38, a current ratio of 5.38 and a debt-to-equity ratio of 0.11. The company has a fifty day moving average price of $4.11 and a 200 day moving average price of $3.68.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.04. On average, research analysts forecast that Compugen will post -0.45 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in CGEN. Wells Fargo & Company MN raised its position in shares of Compugen by 424.5% in the 2nd quarter. Wells Fargo & Company MN now owns 7,526 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 6,091 shares in the last quarter. LPL Financial LLC acquired a new position in shares of Compugen in the 2nd quarter valued at approximately $43,000. Jane Street Group LLC raised its position in shares of Compugen by 20.5% in the 2nd quarter. Jane Street Group LLC now owns 65,721 shares of the biotechnology company’s stock valued at $252,000 after purchasing an additional 11,192 shares in the last quarter. D. E. Shaw & Co. Inc. acquired a new position in shares of Compugen in the 2nd quarter valued at approximately $45,000. Finally, Morgan Stanley raised its position in shares of Compugen by 2.1% in the 2nd quarter. Morgan Stanley now owns 1,035,175 shares of the biotechnology company’s stock valued at $3,975,000 after purchasing an additional 21,368 shares in the last quarter. 29.89% of the stock is currently owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Further Reading: Capital Gains Distribution

Get a free copy of the Zacks research report on Compugen (CGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.